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Abstract 
Background: There are a number of studies regarding to the susceptibility of A20 SNPs in rheumatoid arthritis (RA); 
however, a few of these studies have shown an association between polymorphisms in the A20 gene and RA risk in 
the Chinese population. The aim of this study was to investigate the characteristics of A20 gene polymorphisms, the 
association between polymorphisms and clinical significance in Chinese RA patients.
Methods: PCR and sequencing were used to identify A20 gene polymorphisms in peripheral blood mononuclear 
cells (PBMCs) (50 cases), synovial fluid (11 cases) from RA patients and PBMCs from 30 healthy individuals. Quantitative 
Real-time PCR (qRT-PCR) was used to analyze the A20 mRNA expression in 38 RA patients and 40 healthy individuals. 
Pearson’s Chi square test and two independent-samples Wilcoxon tests were used for statistical analysis.
Results: Eight single nucleotide polymorphisms (SNPs) (rs5029937, rs3799491, rs598493, rs2307859, rs146534657, 
rs2230926, rs661561, and rs582757) were identified in PBMCs of RA patients. One new mutation (14284 T > A) was 
identified in synovial fluid mononuclear cells from one RA case. rs146534657 was identified for the first time in two RA 
cases. Patients with rs146534657 (12411 A > G, Asn102Ser) AG genotype or rs2230926 (12486 T > G, Phe127Cys) TG 
genotype had poor outcome. Significantly lower A20 mRNA expression was found in PBMCs from RA patients com-
pared with healthy individuals (p < 0.001). There was a higher A20 mRNA expression in RA patients with rs2230926 TG 
genotype and rs146534657 AG genotype (11.56 ± 7.39) than patients with rs2230926 TT genotype and rs146534657 
AA genotype (5.63 ± 4.37) (p = 0.031).
Conclusion: Significantly lower A20 expression was found in RA patients. The polymorphisms of A20 were character-
ized in RA patients. We detected rs146534657 for the first time and identified a new A20 mutation (14284 T > A). A20 
rs2230926 TG genotype and rs146534657 AG genotype may be related to poor outcome in RA patients.
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Background
Rheumatoid arthritis (RA) is a systemic autoimmune 
inflammatory disease characterized by proliferative 
synovitis, the infiltration of inflammatory cells into 
synovial tissue, progressive joint destruction and disabil-
ity. Several changes in the T cell compartment have been 
described in immune-mediated diseases [1]. Abnormal T 
cell immunity plays a critical role in the development of 
RA. Inflammatory mediators, such as interleukin-6 (IL-
6), interleukin-1 (IL-1) and tumor necrosis factor alpha 
(TNF-α), are significantly over expressed in RA. Recently, 
RA treatment has been transformed by the development 
of biologics targeting TNF-α and IL-6 [2]. Moreover, 
many inflammatory mediators involved in the pathology 
of RA are regulated by nuclear factor kappa B (NF-κB) 
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transcription factors [3]. Overexpression of NF-κB is a 
common characteristic of RA. Although the RA etiology 
is not fully understood, it is known that a strong genetic 
component plays a major role in this disease [4, 5].
A20, also known as TNFAIP3, was first identified as a 
TNF primary response transcript encoding a 790 amino 
acid protein with a unique zinc finger motif, and it is a 
ubiquitin-editing enzyme that is an essential negative 
regulator of inflammation via its zinc finger domains in 
C-terminus and OUT (ovarian tumor) domain in N-ter-
minus. A20 acts as a negative-feedback regulator of 
NF-κB activation in response to multiple stimuli, includ-
ing TNF, IL-1, TLR (Toll-like receptor) and NLR [Nod 
(nucleotide-binding oligomerization domain)-like recep-
tor] ligands [6, 7].
Genome-wide association studies have implicated the 
A20 locus in susceptibility to multiple autoimmune dis-
eases in different cohorts, including RA, systemic lupus 
erythematosus (SLE), psoriasis, celiac disease, type 1 dia-
betes, inflammatory bowel disease, and coronary artery 
disease. Alterations in the activity or expression of A20 
may influence the pathogenesis of RA [8–10]. Many A20 
single nucleotide polymorphisms (SNPs) were found to 
be associated with the susceptibility to autoimmune dis-
ease [11–13].
There are a number of studies regarding the suscep-
tibility of A20 SNPs in RA [11]. However, only a few of 
these studies have found an association between A20 
gene polymorphisms and the risk of RA in Chinese pop-
ulation [14]. Moreover, there are no data comparing the 
characteristics of A20 polymorphisms and mutations in 
different fluids and tissues of RA. Thus, in this study, we 
analyzed the distribution of A20 gene polymorphisms 
in peripheral blood and synovial fluid as well as the A20 
expression level, and evaluated the potential association 




This study included 50 cases with untreated RA (7 males 
and 43 females, age: 13–74 years, median age: 55.6 years), 
and 40 healthy individuals (6 males and 34 females, age: 
18–70  years, median age: 55.0  years) served as con-
trols. (Among them, DNA samples were isolated from 
50 RA patients and 30 healthy for SNPs analysis, while 
RNA samples were isolated from 38 RA patients and 40 
healthy individuals for A20 gene expression level detec-
tion). There was no significant difference in the distri-
bution of the genders or ages between the cases and 
controls. RA diagnoses were based on the American Col-
lege of Rheumatology criteria and expert opinion (1987 
ACR criteria) [15]. All RA patients were assessed for 
clinical disease activity by a trained rheumatologist using 
disease activity score 28 (DAS 28), and their erythrocyte 
sedimentation rate (ESR), C reactive protein (CRP), rheu-
matoid factor (RF), and anti-cyclic citrullinated peptide 
antibody (CCP) were collected [16]. RF and CRP were 
measured by immune nephelometry, and anti-CCP anti-
body was measured by enzyme-linked immunoabsorbent 
assay (ELISA). In the active phase, all of the parameters 
were abnormal, including the ESR: 69.61 ± 34.63 mm/h, 
CRP: 35.67  ±  28.68  mg/l, RF: 247.89  ±  377.42  IU/ml, 
DAS28: 7.50  ±  1.28, and anti-CCP antibody positiv-
ity was found for 29 patients, while anti-CCP antibody 
negativity was found for 16 patients, anti-CCP antibody 
was not detected in 5 patients. The healthy individuals 
were in healthy status without any cancer, type 2 diabe-
tes, hypertension, or autoimmune inflammatory disease. 
Neither RA patients nor healthy individuals smoked. 
Peripheral blood mononuclear cells (PBMCs) were iso-
lated from heparinized venous blood by Ficoll-Paque 
gradient centrifugation. The synovial fluid was collected 
from RA patients whose knees were examined for thera-
peutic purpose. RNA and DNA extraction and cDNA 
synthesis from PBMCs were performed according to the 
manufacturer’s instructions (Trizol, Invitrogen, USA, 
and Superscript III Kit, Gibco, Gaithersburg, MD, USA) 
[17, 18]. All procedures were conducted according to the 
guidelines of the Medical Ethics Committee of the Health 
Bureau of the Guangdong Province in China.
PCR and sequencing
To amplify different domains of genomic DNA that cover 
A20 exons 2–9 (coding region) and exon/intron junc-
tions of the A20 gene according to the structure of the 
A20 gene, 11 pairs of primers were purchased (Addi-
tional file 1: Table S1). PCR was performed as described 
in our previous study [19]. The PCR products were used 
for mutation analysis of the A20 coding sequence by 
direct sequencing using the Big Dye Terminator v3.1 
Cycle Sequencing Kit (Perkin Elmer, ABI) and the ABI 
PRISM 3100-Avant genetic analyzer. Direct sequencing 
was performed by Invitrogen Biotechnology Company. 
Sequences of different samples from patients with RA 
and healthy individuals were analyzed with BLAST soft-
ware (http://blast.ncbi.nlm.nih.gov/Blast.cgi) to identify 
polymorphisms or mutations in the A20 gene.
Quantitative Real‑time PCR (qRT‑PCR)
To compare the A20 mRNA expression level, qRT-PCR 
was performed using specific A20 primers (Additional 
file 1: Table S1), and the relative amount of the genes of 
interest and the β2M reference gene was measured in 
two independent assays. Specific amplification of the 
PCR products was analyzed by melting curve analysis. 
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The data were presented as the relative expression of the 
genes of interest compared with the internal control gene 
as determined by the 2(−∆CT) method. qRT-PCR was 
performed as previously described [20–22].
Statistical analysis
All statistical analyses were performed with SPSS (v. 13.0) 
software. A P value of less than 0.05 was considered sta-
tistically significant. Pearson’s Chi square test was used to 
compare the distribution of genotypes and alleles between 
RA group and healthy control group. In cases in which 
the genotype had a frequency of less than 1, Fisher’s exact 
test was applied. Two independent-samples Wilcoxon 
tests were performed to compare the median A20 mRNA 
expression level of RA group and controls group.
Results
The distribution and frequency of A20 SNPs in RA
We used 11 primer pairs, which cover the A20 coding 
region, and several introns to amplify segments of A20 
genomic DNA, and positive PCR products were con-
firmed by sequencing. DNA samples from 50 cases with 
RA and 30 healthy individuals were selected for this 
part of the study. We detected eight SNPs of A20 gene: 
rs5029937 (position 11571 with a nucleotide substitution 
of G to T), rs3799491 (position 11812, G > A), rs598493 
(position 11822, T  >  C), rs2307859 (position 12387–
12389 delCCT), rs146534657 (position 12411, A  >  G, 
resulting in an amino acid substitution at position 102 
from asparagine to serine, Asn 102 Ser), rs2230926 (posi-
tion 12486, T > G, resulting in an amino acid substitution 
at position 127 from phenylalanine to cysteine, Phe-
127Cys), rs661561 (position 13751, A > C) and rs582757 
(position 14244, C > T).
Most SNPs are located in intron 2 and 5, while two 
SNPs (rs146534657 and rs2230926) are located in exon 
3 (Table  1; Figures  1, 2). However, the SNP frequencies 
appeared to be lower in the detected samples; the high-
est frequency was 24% (12/50 cases) for rs3799491 GA/
AA genotype, and the lowest was 4.0% (2/50 case) for 
rs5029937 GT genotype, rs146534657 AG genotype, and 
without rs2307859 genotype respectively. In addition, 
the genotypes of four SNPs, rs2307859 (CCT deletion), 
rs661561 (homozygous), rs582757 (homozygous) and 
rs598493 (homozygous), appeared to be common genetic 
alterations in RA as they were identified in 41 cases, while 
the remaining 9 cases demonstrated different genotypic 
characteristics. However, 6 of the 8 SNPs were also iden-
tified in the healthy control group with similar frequency, 
and rs146534657 AG genotype and rs2307859 wild geno-
type were not identified in the healthy controls. How-
ever, there was no statistically significant difference in the 
proportion of genotypic data between the RA group and 
healthy group (Table  2). Moreover, genetic alterations in 
RA and healthy samples with the rs2230926 TG genotype 
and/or rs146534657 AG genotype were different from 
those lacking both SNPs (Table 3).
Characteristics of A20 SNPs in synovial fluid from RA 
patients
We further analyzed the characteristics of A20 SNPs in 
cells from the synovial fluid and PBMCs from 11 cases 
with RA whose knees were examined for therapeutic 
purpose at the same time as peripheral blood collec-
tion. A total of seven A20 SNPs (rs5029937, rs3799491, 
rs598493, rs2307859, rs2230926, rs661561 and rs582757) 
were identified. The identical SNPs in the synovial fluid 
and peripheral blood were identified in 10 RA cases 
(Table 4), and a new mutation (14284 T > A) was iden-
tified in synovial fluid from only one RA case whose 
peripheral blood sample did not contain this mutation 
(Table 4; Figure 3).
The association between A20 SNPs and A20 expression 
level
We analyzed the A20 expression level in cDNA sam-
ples from 38 RA patients and 40 healthy individuals by 
real-time PCR, and a significantly lower A20 expres-
sion level (5.96 ± 4.82) was found compared with that in 
healthy individuals (34.54 ± 26.89) (p < 0.001) (Figure 4). 
We also compared the A20 expression level of different 
SNPs, it appeared that there was a higher A20 expression 
level in RA patients with rs2230926 TG genotype and 
rs146534657 AG genotype (11.56  ±  7.39) than patients 
with rs2230926 TT genotype and rs146534657 AA gen-
otype (5.63 ±  4.37) (P =  0.031) (Figure  5). In addition, 
there was no significant difference of A20 expression 
level between RA patients with rs3799491 AA/GA gen-
otypes (6.75  ±  5.25) and with rs3799491 GG genotype 
Table 1 Identified SNPs of the A20 gene in PBMCs and syn-
ovial fluid from RA





rs5029937 137874014 Intron 2 G/T –
rs3799491 137874255 Intron 2 G/A –
rs598493 137874265 Intron 2 C/T –
rs2307859 137874830 Intron 2 12387_12389 
delCCT
–
rs146534657 137874854 Exon 3 A/G Asn102Ser
rs2230926 137874929 Exon 3 T/G Phe127Cys
rs661561 137876194 Intron 5 C/A –
rs582757 137876687 Intron 5 T/C –
NEW1 (14284) 137876727 Intron 5 T/A –
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(5.61 ± 4.79) (P = 0.560) (Figure 6a). The A20 expression 
level in RA patients with rs661561 AA/AC genotypes 
(7.23 ± 6.82) appeared to be higher than with rs661561 
CC genotype (5.59 ±  4.47); however, there was also no 
significant difference (p = 0.452) (Figure 6b).
The association between A20 alteration and RA clinical 
characteristics
First, we compared the difference of SNPs and the sta-
tus in RA patients with or without anti-CCP antibody 
positive, we found there were no correlation between 
the eight SNPs and anti-CCP antibody. We also found 
that there was no significant difference of A20 expression 
level between anti-CCP antibody positive and anti-CCP 
antibody negative RA groups (P > 0.05).
Among the 50 RA patients, rs2230926 TG genotype 
was identified in 3 RA patients, one patient both with 
rs2230926 TG genotype and rs146534657 AG genotype 
was poor response to immune suppression therapy, such 
as methotrexate, infliximab and anti-TNF-α antibody; the 
second and the third patients both with rs2230926 TG 
genotype and rs5029937 GT genotype suffered severe 
disease with systemic joint destruction. rs146534657 AG 
genotype was identified in two RA patients, the second 
patient suffered obvious joint deformity in multiple joints 
of the hands and the knee. Overall, the SNPs rs2230926 
and/or rs146534657, which located in exon 3, appeared 
to be related to poor clinical outcome in RA. Moreover, 
there were no significantly different clinical character-
istics for the patient with the newly detected mutation 
(14284 T > A).
Discussion
A20 plays a central role in the control of NF-kB activa-
tion, A20 also negative regulates NLRP3 inflammasome 
to protect against arthritis [23]. It is known to be associ-
ated with susceptibility to multiple autoimmune diseases 
[6]. Polymorphisms and mutations in the A20 gene are 
linked to various autoimmune diseases. Recent stud-
ies from different countries have reported that A20 is 
frequently inactivated by deletions and/or mutations in 
autoimmune diseases, including RA [11]. Previous stud-
ies of A20 in RA have demonstrated an association with 
several disease risk SNPs, including rs2230926, rs6920220 
and rs10499194 [24]. However, the frequencies of the 
reported A20 abnormalities in different reports are dis-
similar. Moreover, our previous study suggested that the 
A20 polymorphisms associated with disease susceptibil-
ity may be different for different ethnic groups [19]. Little 
is known about the genetic alteration characteristics of 
A20 gene in Chinese population. In this study, we evalu-
ated the role of the polymorphisms in the A20 gene on 
the risk for RA.
A number of studies have demonstrated a strong asso-
ciation between rs2230926 and RA, and this SNP plays a 
functional role in the development of RA. rs2230926 is 
located in exon 3 of A20, and results in an amino acid (at 
127 position) substitution from phenylalanine to cysteine 
(Phe127Cys). This risk allele (Cys127) leads to reduced 
inhibition of NF-kB activation or reduced A20 mRNA 
levels [25]. There is a significant association between 
rs2230926 and increased risk for SLE and RA in the Japa-
nese population [26]. Moreover, the rs2230926 polymor-
phism is associated with RA susceptibility in Europeans 
and Asians [24]. In this study, we found only three cases 
with rs2230926 TG genotype in 50 RA samples; however, 
we also found two cases with rs2230926 TG genotype 
among 30 healthy individuals. Therefore, this prelimi-
nary result may indicate a lower incidence of rs2230926 
TG/GG genotype in Chinese RA patients, as least in 
our study group. Although patients with rs2230926 TG 
genotype demonstrated refractory and poorer outcome, 
there was no significant association between RA patients 
and healthy individuals, which was similar to findings 
in our previous study on T cell acute lymphoblastic leu-
kemia (T-ALL) [19]. Analogous results were reported 
Figure 1 Location of SNPs in the A20 gene locus.
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by Orozco et  al. who found that rs2230926 is not inde-
pendently associated with RA [27]. In addition, findings 
from a Korean group showed that rs2230926 in A20 is 
not associated with RA susceptibility in the Korean pop-
ulation [28]. However, results from Zhang et al. showed 
that rs2230926 is associated with RA risk in the north-
ern Chinese population [29]. Because the RA patients 
and healthy individuals in this study were all from south-
ern China, whether there are different genotypes of A20 
gene in northern and southern Chinese people remains 
Figure 2 Identification of A20 SNPs in RA patients. Arrows indicate sites of nucleotide changes. Wild wild-type, Homo homozygous, Heter heterozy-
gous.
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Table 2 Frequencies of the alleles and genotypes of the A20 polymorphisms in RA patients (case) and healthy individuals 
(control)
n number of participants.
* Fisher’s exact p value.
SNPs Genotype frequency n (%) Allele frequency n (%)
Major homozygote Heterozygote Minor homozygote Major allele Minor allele
rs5029937 GG GT TT G T
 Case 48 (96.0) 2 (4.0) 0 (0) 98 (98.0) 2 (2.0)
 Control 28 (93.3) 2 (6.7) 0 (0) 58 (96.7) 2 (3.3)
 p-value – 1.000 – 1.000
rs3799491 GG GA AA GA/AA G A
 Case 38 (76.0) 11 (22.0) 1 (2.0) 12 (24) 87 (87.0) 13 (13.0)
 Control 21 (70.0) 9 (30.0) 0 (0) 9 51 (85.0) 9 (15.0)
 p-value – 0.454 1.000* 0.555 – 0.722
rs598493 CC TC TT C T
 Case 44 (88.0) 6 (12.0) 0 (0) 94 (94.0) 6 (6.0)
 Control 26 (86.7) 4 (13.3) 0 (0) 56 (93.3) 4 (6.7)
 p-value – 1.000 – 1.000
rs2307859 –/CCT Wild type
 Case 48 (96.0) 2 (4.0)
 Control 30 (100) 0 (0)
 p-value – 0.525*
rs146534657 AA AG GG A G
 Case 48 (96.0) 2 (4.0) 0 (0) 98 (98.0) 2 (2.0)
 Control 30 (100) 0 (0) 0 (0) 60 (100) 0 (0)
 p-value – 0.525* – 0.528*
rs2230926 TT TG GG T G
 Case 47 (94.0) 3 (6.0) 0 (0) 97 (97.0) 3 (3.0)
 Control 28 (93.3) 2 (6.7) 0 (0) 58 (96.7) 2 (3.3)
 p-value – 1.000 – 1.000
rs661561 CC AC AA AC/AA C A
 Case 41 (82.0) 8 (16.0) 1 (2.0) 9 (18) 90 (90.0) 10 (10.0)
 Control 24 (80) 6 (20) 0 (0) 6 (20) 54 (90.0) 6 (10.0)
 p-value – 0.678 1.000* 0.824 – 1.000
rs582757 TT CT CC T C
 Case 44 (88.0) 6 (12.0) 0 (0) 94 (94.0) 6 (6.0)
 Control 26 (86.7) 4 (13.3) 0 (0) 56 (93.3) 4 (6.7)
 p-value – 1.000 – 1.000
Table 3 A20 genetic alterations with rs230926 and rs146534657 in PBMCs of RA patients and healthy individuals
HI healthy individuals, Wild wild-type, Homo homozygous, Heter heterozygous, Del deletion.
a RA cases.
Cases rs5029937 rs3799491 rs598493 rs2307859 rs146534657 rs2230926 rs661561 rs582757
PHLa Wild Wild Homo Wild Heter Heter Wild Homo
LXSa Wild Heter Homo Del Heter Wild Heter Homo
WYFa Heter Wild Homo Wild Wild Heter Heter Homo
LWLa Heter Wild Homo Del Wild Heter Homo Homo
HI1 Heter Wild Homo Del Wild Heter Heter Homo
HI2 Heter Heter Homo Del Wild Heter Heter Homo
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an open question. An alternative may be that, due to the 
limited samples in this study, the association between 
rs2230926 and RA in Chinese population requires fur-
ther investigation with a greater number of samples.
Interestingly, we found two RA patients with 
rs2230926 TG genotype did not accompany rs2307859 
(CCT deletion) which was a common alteration in 48 
RA patients and 30 healthy individuals, it may be pos-
sible that absence of rs2307859 genotype is a risk fac-
tor to RA when rs2230926 TG genotype is present. 
Moreover, the genetic alteration of A20 in one patient 
with both rs2230926 TG genotype and rs146534657 
Table 4 A20 gene polymorphism characteristics in peripheral blood and synovial fluid from RA patients
B peripheral blood, S synovial fluid, Wild wild-type, Homo homozygous, Heter heterozygous, Del deletion.
Case no. Samples rs5029937 rs3799491 rs598493 rs2307859 rs2230926 rs661561 rs582757 14284 T > A
1 S Wild Wild Homo Del Wild Homo Homo Wild
B Wild Wild Homo Del Wild Homo Homo Wild
2 S Wild Wild Homo Del Wild Homo Homo Wild
B Wild Wild Homo Del Wild Homo Homo Wild
3 S Wild Wild Heter Del Wild Heter Heter Wild
B Wild Wild Heter Del Wild Heter Heter Wild
4 S Wild Wild Homo Del Wild Homo Homo Heter
B Wild Wild Homo Del Wild Homo Homo Wild
5 S Wild Wild Homo Del Wild Homo Homo Wild
B Wild Wild Homo Del Wild Homo Homo Wild
6 S Heter Wild Homo Wild Heter Heter Homo Wild
B Heter Wild Homo Wild Heter Heter Homo Wild
7 S Wild Homo Homo Del Wild Homo Homo Wild
B Wild Homo Homo Del Wild Homo Homo Wild
8 S Wild Wild Homo Del Wild Homo Homo Wild
B Wild Wild Homo Del Wild Homo Homo Wild
9 S Wild Wild Homo Del Wild Homo Homo Wild
B Wild Wild Homo Del Wild Homo Homo Wild
10 S Wild Heter Homo Del Wild Homo Homo Wild
B Wild Heter Homo Del Wild Homo Homo Wild
11 S Wild Wild Homo Del Wild Homo Homo Wild
B Wild Wild Homo Del Wild Homo Homo Wild
Figure 3 New mutation identified in A20 in synovial fluid from a 
patient with RA. Arrows indicate sites of nucleotide changes. Wild 
wild-type, Heter heterozygous.
Figure 4 A20 expression level in RA patients and healthy individuals 
(HI).
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AG genotype and poor outcome appeared to be differ-
ent from most RA patients because it appeared with 
rs661561 AA genotype, which was found in almost 
all of the RA patients and healthy individuals with 
homozygous (CC genotype) or heterozygous (AC gen-
otype) [30]. Whether such genetic alterations in A20 
leads to high risk for RA needs further investigation. In 
addition, similar genetic alterations in A20 were identi-
fied in T-ALL [19].
In this study, we detected rs146534657 for the first 
time in two RA patients. This SNP which was described 
in GenBank but not identified for any disease, is a non-
synonymous variant located in exon 3 of A20 and results 
in an amino acid (at position 102) substitution from 
asparagine to serine (Asn 102 Ser). According to the 
clinical information of the patients, those who had both 
rs2230926 TG genotype and rs146534657 AG geno-
type had poor outcome, and whether rs2230926 and 
rs146534657 are associated with refractory RA requires 
further investigation with more samples to demonstrate.
In this study, we also analyzed the alteration of SNPs 
in A20 that were reported in different autoimmune dis-
eases, such as rs5029937, which was strongly associated 
with RA in a large European RA cohort [27, 31] and sig-
nificantly associated with SLE in southwestern Chinese 
population [32]; rs582757, which was reported to be 
associated with rheumatic heart disease (RHD) in the 
Chinese Han population [33] and weakly associated with 
reduced risk for RA in Caucasians [34], also associated 
with psoriasis [35]; rs598493, which was significantly 
increased in the GG genotype in Graves’ disease (GD) 
[30]; and rs3799491, which has not been reported in RA 
or other diseases. However, in this study, rs5029937 GT 
genotype was identified only in two RA patients who 
with rs2230926 TG genotype and suffered severe disease 
with systemic joint destruction, and whether rs5029937 
is associated with the destruction of bone and cartilage 
in RA need further investigation. Moreover, rs582757 
and rs598493 were identified in all samples including RA 
patients and healthy individuals as having a homozygous 
or heterozygous genotype; thus, it could be concluded 
that these are a common genotype in the Chinese popula-
tion. In addition, rs3799491 GA/AA genotype was found 
in 12 out of 50 RA patients and 9 out of 30 healthy indi-
viduals, and we found no significant difference in these 
alterations between RA patients and healthy individuals. 
These results may indicate that the A20 polymorphisms 
associated with RA susceptibility are different in different 
populations.
To define the A20 gene polymorphism characteristics 
of synovial fluid from RA patients, we compared A20 
Figure 5 Comparison of A20 expression level between SNPs (RA 
patients with rs2230926 TG genotype and rs146534657 AG genotype) 
and WT (RA patients with rs2230926 TT genotype and rs146534657 
AA genotype).
Figure 6 Comparison of the A20 expression level between samples with rs3799491 or rs661561 SNPs. a A20 expression level in patients with 
rs3799491 AA/GA genotypes and with rs3799491 GG genotype. b A20 expression level in patients with rs661561 AA/AC genotypes (heterozygous) 
and with rs661561 CC genotype (homozygous).
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polymorphisms in samples from peripheral blood and 
synovial fluid from 11 RA patients. Interestingly, one 
new mutation (14284 T  >  A) was identified in synovial 
fluid from one RA patient. This result may indicate the 
possibility of inconsistent genetic alterations in differ-
ent tissues from the same patient. However, the signifi-
cance and frequency of this new mutation need further 
investigation.
As a NF-kB negative regulator, A20 is critical for lim-
iting inflammation by terminating TNF-induced NF-kB 
responses in vivo [36]. We also analyzed the A20 expres-
sion level in PBMCs of RA patients, and a significantly 
lower A20 expression level may be related to enhanced 
NF-kB and RA pathogenesis [22, 37]. There was a nega-
tive relationship between the A20 mRNA expression level 
and RA activity. Interestingly, PBMCs from RA patients 
with the rs2230926 TG genotype and rs146534657 AG 
genotype had a higher A20 expression level compared 
with RA patients with rs2230926 TT genotype and 
rs146534657 AA genotype, and a similar finding was 
reported for T-ALL in our previous study [19]. This result 
may imply that such a rs2230926 TG genotype may be 
related to the maintenance of A20 expression level. How-
ever, this hypothesis is based only on results from a lim-
ited case analysis, and further research involving more 
samples is needed to determine representative results. 
Moreover, this finding appeared to be inconsistent with 
the disease status of patients; thus, remaining an open 
question.
Conclusion
In conclusion, we characterized the A20 gene polymor-
phisms of RA, detected the SNP rs146534657 for the first 
time in RA, and found a new mutation (14284 T  >  A) 
in synovial fluid of RA. Our data suggested that the 
rs2230926 TG genotype and rs146534657 AG genotype 
might be related to RA poor outcome. Significantly lower 
A20 mRNA expression was found in RA patients. How-
ever, further research involving more samples is needed 
to determine representative results.
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